Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802788698> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2802788698 endingPage "e21" @default.
- W2802788698 startingPage "e17" @default.
- W2802788698 abstract "To report the rate of bone morphogenetic protein-2 (BMP-2) use in vertebral column tumor surgery.The Nationwide Inpatient Sample database (2012-2014) was queried to identify patients who underwent spinal fusion for vertebral column tumors (primary benign, primary malignant, or metastatic). The rate of BMP-2 use was calculated, and patient and operative factors associated with its use were also investigated.We identified 9375 patients who underwent fusion surgery for spinal tumors between 2012 and 2014, with 540 cases using BMP-2 (5.8%). Preoperative diagnosis revealed that the rate of BMP-2 use in primary benign tumor surgery was 4.9%, 7.6% for primary malignant tumors, and 5.7% for metastatic lesions (P = 0.607). The overall complication rate was 13.2% (13.4% in the NO-BMP-2 group vs. 11.1% in the BMP-2 group; P = 0.504). Patients who received this growth factor were less likely to have epidural spinal cord compression at presentation (37.0% vs. 49.2%; P = 0.014), and more likely to have elective surgery (53.7% vs. 37.7%; P < 0.001). Analysis of hospital location indicated that the highest use of BMP-2 was in the South (7.4% rate; P = 0.002). There was no statistical difference between age, sex, insurance status, comorbidities, the presence of a pathologic fracture, or the use of inpatient radiotherapy or chemotherapy between patients who received BMP-2 and controls.BMP-2 has been used off-label to promote arthrodesis; however, its use in patients with spinal tumors is controversial. In this national study, BMP-2 use was highest in the South, in patients without epidural cord compression at presentation, and in elective cases." @default.
- W2802788698 created "2018-05-17" @default.
- W2802788698 creator A5010068058 @default.
- W2802788698 creator A5014224271 @default.
- W2802788698 creator A5014878334 @default.
- W2802788698 creator A5032452111 @default.
- W2802788698 creator A5063637296 @default.
- W2802788698 creator A5076430359 @default.
- W2802788698 creator A5079686298 @default.
- W2802788698 creator A5088026749 @default.
- W2802788698 date "2018-09-01" @default.
- W2802788698 modified "2023-09-26" @default.
- W2802788698 title "Use of Bone Morphogenetic Protein-2 in Vertebral Column Tumor Surgery: A National Investigation" @default.
- W2802788698 cites W1968822620 @default.
- W2802788698 cites W2039839585 @default.
- W2802788698 cites W2071756412 @default.
- W2802788698 cites W2074645659 @default.
- W2802788698 cites W2079298550 @default.
- W2802788698 cites W2088794241 @default.
- W2802788698 cites W2108166915 @default.
- W2802788698 cites W2331589472 @default.
- W2802788698 cites W2411728278 @default.
- W2802788698 cites W2503267153 @default.
- W2802788698 cites W2561653982 @default.
- W2802788698 cites W2589581131 @default.
- W2802788698 cites W2590275103 @default.
- W2802788698 cites W2609288179 @default.
- W2802788698 cites W2722867918 @default.
- W2802788698 doi "https://doi.org/10.1016/j.wneu.2018.04.190" @default.
- W2802788698 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29733987" @default.
- W2802788698 hasPublicationYear "2018" @default.
- W2802788698 type Work @default.
- W2802788698 sameAs 2802788698 @default.
- W2802788698 citedByCount "5" @default.
- W2802788698 countsByYear W28027886982019 @default.
- W2802788698 countsByYear W28027886982020 @default.
- W2802788698 countsByYear W28027886982021 @default.
- W2802788698 countsByYear W28027886982023 @default.
- W2802788698 crossrefType "journal-article" @default.
- W2802788698 hasAuthorship W2802788698A5010068058 @default.
- W2802788698 hasAuthorship W2802788698A5014224271 @default.
- W2802788698 hasAuthorship W2802788698A5014878334 @default.
- W2802788698 hasAuthorship W2802788698A5032452111 @default.
- W2802788698 hasAuthorship W2802788698A5063637296 @default.
- W2802788698 hasAuthorship W2802788698A5076430359 @default.
- W2802788698 hasAuthorship W2802788698A5079686298 @default.
- W2802788698 hasAuthorship W2802788698A5088026749 @default.
- W2802788698 hasConcept C104317684 @default.
- W2802788698 hasConcept C118552586 @default.
- W2802788698 hasConcept C141071460 @default.
- W2802788698 hasConcept C142724271 @default.
- W2802788698 hasConcept C185592680 @default.
- W2802788698 hasConcept C204787440 @default.
- W2802788698 hasConcept C2778231337 @default.
- W2802788698 hasConcept C2780375110 @default.
- W2802788698 hasConcept C2780775167 @default.
- W2802788698 hasConcept C2781298600 @default.
- W2802788698 hasConcept C31507581 @default.
- W2802788698 hasConcept C55493867 @default.
- W2802788698 hasConcept C71924100 @default.
- W2802788698 hasConcept C81182388 @default.
- W2802788698 hasConceptScore W2802788698C104317684 @default.
- W2802788698 hasConceptScore W2802788698C118552586 @default.
- W2802788698 hasConceptScore W2802788698C141071460 @default.
- W2802788698 hasConceptScore W2802788698C142724271 @default.
- W2802788698 hasConceptScore W2802788698C185592680 @default.
- W2802788698 hasConceptScore W2802788698C204787440 @default.
- W2802788698 hasConceptScore W2802788698C2778231337 @default.
- W2802788698 hasConceptScore W2802788698C2780375110 @default.
- W2802788698 hasConceptScore W2802788698C2780775167 @default.
- W2802788698 hasConceptScore W2802788698C2781298600 @default.
- W2802788698 hasConceptScore W2802788698C31507581 @default.
- W2802788698 hasConceptScore W2802788698C55493867 @default.
- W2802788698 hasConceptScore W2802788698C71924100 @default.
- W2802788698 hasConceptScore W2802788698C81182388 @default.
- W2802788698 hasLocation W28027886981 @default.
- W2802788698 hasLocation W28027886982 @default.
- W2802788698 hasOpenAccess W2802788698 @default.
- W2802788698 hasPrimaryLocation W28027886981 @default.
- W2802788698 hasRelatedWork W1970975471 @default.
- W2802788698 hasRelatedWork W1997732943 @default.
- W2802788698 hasRelatedWork W2069721889 @default.
- W2802788698 hasRelatedWork W2101430383 @default.
- W2802788698 hasRelatedWork W2182927526 @default.
- W2802788698 hasRelatedWork W2320980343 @default.
- W2802788698 hasRelatedWork W2383286245 @default.
- W2802788698 hasRelatedWork W2417961914 @default.
- W2802788698 hasRelatedWork W2474039552 @default.
- W2802788698 hasRelatedWork W2945124548 @default.
- W2802788698 hasVolume "117" @default.
- W2802788698 isParatext "false" @default.
- W2802788698 isRetracted "false" @default.
- W2802788698 magId "2802788698" @default.
- W2802788698 workType "article" @default.
%20use%20in%20vertebral%20column%20tumor%20surgery.The%20Nationwide%20Inpatient%20Sample%20database%20(2012-2014)%20was%20queried%20to%20identify%20patients%20who%20underwent%20spinal%20fusion%20for%20vertebral%20column%20tumors%20(primary%20benign%2C%20primary%20malignant%2C%20or%20metastatic).%20The%20rate%20of%20BMP-2%20use%20was%20calculated%2C%20and%20patient%20and%20operative%20factors%20associated%20with%20its%20use%20were%20also%20investigated.We%20identified%209375%20patients%20who%20underwent%20fusion%20surgery%20for%20spinal%20tumors%20between%202012%20and%202014%2C%20with%20540%20cases%20using%20BMP-2%20(5.8%25).%20Preoperative%20diagnosis%20revealed%20that%20the%20rate%20of%20BMP-2%20use%20in%20primary%20benign%20tumor%20surgery%20was%204.9%25%2C%207.6%25%20for%20primary%20malignant%20tumors%2C%20and%205.7%25%20for%20metastatic%20lesions%20(P%20%3D%200.607).%20The%20overall%20complication%20rate%20was%2013.2%25%20(13.4%25%20in%20the%20NO-BMP-2%20group%20vs.%2011.1%25%20in%20the%20BMP-2%20group%3B%20P%20%3D%200.504).%20Patients%20who%20received%20this%20growth%20factor%20were%20less%20likely%20to%20have%20epidural%20spinal%20cord%20compression%20at%20presentation%20(37.0%25%20vs.%2049.2%25%3B%20P%20%3D%200.014)%2C%20and%20more%20likely%20to%20have%20elective%20surgery%20(53.7%25%20vs.%2037.7%25%3B%20P%20%3C%200.001).%20Analysis%20of%20hospital%20location%20indicated%20that%20the%20highest%20use%20of%20BMP-2%20was%20in%20the%20South%20(7.4%25%20rate%3B%20P%20%3D%200.002).%20There%20was%20no%20statistical%20difference%20between%20age%2C%20sex%2C%20insurance%20status%2C%20comorbidities%2C%20the%20presence%20of%20a%20pathologic%20fracture%2C%20or%20the%20use%20of%20inpatient%20radiotherapy%20or%20chemotherapy%20between%20patients%20who%20received%20BMP-2%20and%20controls.BMP-2%20has%20been%20used%20off-label%20to%20promote%20arthrodesis%3B%20however%2C%20its%20use%20in%20patients%20with%20spinal%20tumors%20is%20controversial.%20In%20this%20national%20study%2C%20BMP-2%20use%20was%20highest%20in%20the%20South%2C%20in%20patients%20without%20epidural%20cord%20compression%20at%20presentation%2C%20and%20in%20elective%20cases.%22){kind=link}